851070-45-6 Usage
Uses
Used in Pharmaceutical Industry:
[4-cyclopropyl-2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile is used as a building block for the synthesis of potential drug candidates. Its unique structure and functional groups make it a valuable component in the development of new medications.
Used in Medicinal Chemistry Research:
[4-cyclopropyl-2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile is also utilized in medicinal chemistry research to explore its biological activity and potential interactions with biological targets. Its properties may lead to the discovery of novel therapeutic agents or contribute to the understanding of certain biological processes.
It is crucial to handle [4-cyclopropyl-2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile with care, as it may possess hazardous properties and should be used in a controlled laboratory setting to ensure safety and proper containment.
Check Digit Verification of cas no
The CAS Registry Mumber 851070-45-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,0,7 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 851070-45:
(8*8)+(7*5)+(6*1)+(5*0)+(4*7)+(3*0)+(2*4)+(1*5)=146
146 % 10 = 6
So 851070-45-6 is a valid CAS Registry Number.
851070-45-6Relevant academic research and scientific papers
Amide bridged piphenyl or biazaphenyl derivatives
-
Page/Page column 30, (2008/06/13)
This invention is concerned with compounds of the formula wherein one of R5, R6 and R7 is and R1 to R13, X1, X2, m and n are defined in the description, and all pharmaceutically
Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents
-
Page/Page column 31, (2008/06/13)
This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.
